Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk

被引:19
作者
Zhang, Hongtuan [1 ]
Wang, Andi [1 ,2 ]
Ma, Hui [3 ]
Xu, Yong [1 ,2 ]
机构
[1] Tianjin Med Univ, Affiliated Hosp 2, Tianjin Key Lab Urol, Natl Key Clin Specialty Urol, Tianjin 300211, Peoples R China
[2] Tianjin Key Lab Urol, Tianjin, Peoples R China
[3] Tianjin Med Univ, Affiliated Hosp 2, Dept Obstet & Gynaecol, Tianjin 300211, Peoples R China
关键词
Insulin receptor substrate 1; Polymorphism; Cancer; Meta-analysis; Association; GROWTH-FACTOR-I; COLORECTAL-CANCER; BREAST-CANCER; PROSTATE-CANCER; GENETIC POLYMORPHISMS; NO ASSOCIATION; RECTAL-CANCER; UNITED-STATES; IRS1; SUSCEPTIBILITY;
D O I
10.1007/s13277-013-0855-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epidemiological studies investigating the association between the insulin receptor substrate 1 (IRS1) gene Gly972Arg (rs1801278) polymorphism and various carcinomas risk reported conflicting results. Thus, a systemic review and meta-analysis of published studies were performed to assess the possible association. A comprehensive search was conducted to identify all eligible studies of IRS1 Gly972Arg polymorphism and cancer risk. Odds ratios (ORs) and 95 % confidence intervals (CIs) were used to assess the strength of the associations. A total of 16 independent studies, including 11,776 cases and 11,654 controls, were identified. When all studies were pooled, we found a significant association between IRS1 Gly972Arg polymorphism and increased cancer risk under dominant model (OR = 1.16, 95 %CI = 1.04-1.30, P = 0.007) and allelic model (OR = 1.16, 95 %CI = 1.02-1.30, P = 0.02). In subgroup analysis based on cancer type, increased cancer risk was found in ovarian cancer (dominant: OR = 1.55, 95 %CI = 1.17-2.05, P = 0.002; allelic: OR = 1.55, 95 %CI = 1.19-2.01, P = 0.001), breast cancer (allelic: OR = 1.12, 95 %CI = 1.00-1.26, P = 0.05), and other cancers (allelic: OR = 1.31, 95 %CI = 1.00-1.71, P = 0.05). When stratified by study types, significant associations were observed in both cohort studies (dominant: OR = 1.25, 95 %CI = 1.06-1.47, P = 0.007; allelic: OR = 1.25, 95 %CI = 1.07-1.46, P = 0.005) and case-control studies (dominant: OR = 1.15, 95 %CI = 1.01-1.31, P = 0.04). In the subgroup analyses by ethnicity, significantly increased cancer risk was suggested among both Caucasians (dominant: OR = 1.13, 95 %CI = 1.02-1.26, P = 0.02; allelic: OR = 1.13, 95 %CI = 1.03-1.25, P = 0.01) and mixed population (dominant: OR = 1.22, 95 %CI = 1.01-1.46, P = 0.04). Our investigations demonstrate that IRS1 Gly972Arg polymorphism was associated with an increased risk of cancer, and additional well-designed studies are warranted to validate these findings.
引用
收藏
页码:2929 / 2936
页数:8
相关论文
共 50 条
  • [31] Insulin receptor substrate 2 gene Gly1057Asp polymorphism is a risk factor for nonalcoholic fatty liver disease
    Nouri, Shadi
    Mahmoudi, Touraj
    Hojjati, Farzaneh
    Najafabadi, Zeinab Nourmohammadi
    Shafiee, Radmehr
    Sayedsalehi, Shiva
    Dehghanitafti, Atefeh
    Ardalani, Abbas
    Kohansal, Kiarash
    Rezamand, Gholamreza
    Asadi, Asadollah
    Nobakht, Hossein
    Dabiri, Reza
    Farahani, Hamid
    Tabaeian, Seidamir Pasha
    Zali, Mohammad Reza
    [J]. LABORATORY MEDICINE, 2024, 55 (02) : 215 - 219
  • [32] Association of estrogen receptor-beta (ESR2) polymorphism and cancer risk: a meta-analysis
    Xia, Wenkai
    Wang, Tianyi
    Sun, Dong
    Mao, Weidong
    Xie, Xiangcheng
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2016, 37 (04) : 530 - 538
  • [33] Association between X-ray repair cross-complementing group 1 Arg194Trp polymorphism and colorectal cancer risk
    Mao, Dong
    Zhang, Yun
    Lu, Hang
    Fu, Xiaoguang
    [J]. TUMOR BIOLOGY, 2013, 34 (05) : 2529 - 2538
  • [34] Gly71Arg UGT1A1 polymorphism is associated with breast cancer susceptibility in Han Chinese women
    Shi, J.
    Li, L. H.
    Duan, X. Y.
    Liu, Q.
    Sun, L. L.
    Tian, Y. T.
    [J]. GENETICS AND MOLECULAR RESEARCH, 2016, 15 (03)
  • [35] The Association Between XPG Gene Polymorphism and Gastric Cancer Risk
    Su, Yanyan
    Yang, Chong
    Zhang, Zongxiang
    [J]. GENETIC TESTING AND MOLECULAR BIOMARKERS, 2017, 21 (10) : 619 - 624
  • [36] Association between TP53 Arg72Pro polymorphism and thyroid carcinoma risk
    Wang, Fang
    Wang, Peng
    Wang, Bin
    Fu, Zheng-Ju
    Yuan, Ying
    Yan, Sheng-Li
    Zhao, Wen-Juan
    Wang, Yan-Gang
    [J]. TUMOR BIOLOGY, 2014, 35 (03) : 2723 - 2728
  • [37] No significant association between p53 codon 72 Arg/Pro polymorphism and risk of oral cancer
    Jiang, Ning
    Pan, Jie
    Wang, Lei
    Duan, Yin-Zhong
    [J]. TUMOR BIOLOGY, 2013, 34 (01) : 587 - 596
  • [38] The association between UGT1A7 polymorphism and cancer risk: A meta-analysis
    Han, Shuang-Xi
    Wang, Li
    Wu, De-Quan
    [J]. CANCER EPIDEMIOLOGY, 2012, 36 (04) : E201 - E206
  • [39] Association between CYP1A1 2454A > G polymorphism and colorectal cancer risk: A meta-analysis
    Xu, Liang
    Wei, Hongwei
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (04) : 760 - 764
  • [40] Association between the Estrogen receptor β rs1256049 polymorphism and prostate cancer risk: a meta-analysis
    Gazzaz, Hassane
    El Feniche, Mohammed
    Ameur, Ahmed
    Dami, Abdellah
    [J]. ANNALES DE BIOLOGIE CLINIQUE, 2023, 81 (03) : 280 - 288